Product Platform
Regeneus has developed IP, skills and experience in the area of the separation, preparation and uses of adipose-derived regenerative cells for therapeutic purposes in the human and animal health markets. These technologies comprise two product platforms:
- Cell-based platform (autologous and allogeneic)
- Cell secretions-based platform
AdiCellTM and HiQCellTM are the first autologous product from our cell-based platform. Our primary focus for AdiCell is as a treatment for canine and equine orthopaedic conditions, while HiQCell is our human application.
Regeneus has the capacity and IP coverage in our cell and cell secretions platforms to make "off the shelf" allogeneic products for a range of indications in the human and animal health markets, including orthopaedic conditions, inflammatory conditions, heart disease and wound healing. This gives the company the capacity to develop, trial and if successful, manufacture "off the shelf" biological products for wide distribution.